Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II trial of oxipurinol in autosomal dominant polycystic kidney disease

Next Previous
Trial Profile

A phase II trial of oxipurinol in autosomal dominant polycystic kidney disease

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxipurinol (Primary)
  • Indications Autosomal dominant polycystic kidney disease
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 13 Aug 2018 According to a XORTX Therapeutics media release, the company with its collaborative partner, Cato Clinical Research, has filed its pre-IND meeting documents with the FDA. The meeting with the FDA has been scheduled for September 20, 2018.
    • 28 Jun 2018 According to a XORTX Therapeutics media release, the company has collaboration with The Polycystic Kidney Disease Foundation fo this trial.
    • 08 Jun 2018 According to a XORTX Therapeutics media release, has filed its pre-IND meeting request letter with the FDA.The meeting with the FDA has been scheduled for September 10, 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top